

MATERIAL SAFETY DATA SHEET

PAGE 1

Vecuronium Bromide for Injection

ISSUED 08/03/99

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

MATERIAL NAME: Vecuronium Bromide for Injection

List Number: 1613, 1632, 1634, 1636, 1654, 1655

MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois 60064

EMERGENCY TELEPHONE NUMBER: 1-847-937-7970

CHEMTREC TELEPHONE NUMBER: 1-800-424-9300

2. COMPOSITION/INFORMATION ON INGREDIENTS

INGREDIENT NAME: Vecuronium Bromide *

CAS/RTECS NUMBERS: 50700-72-6 / TN4875C00

OSHA-PEL 8HR TWA: N/L

STEL: N/L

CEILING: N/L

ACGIH-TLV 8HR TWA: N/L

STEL: N/L

CEILING: N/L

OTHER 8HR TWA: 5 mcg/m3 (Abbott Laboratories)

LIMITS STEL: 20 mcg/m3

CEILING: N/A

* Hazardous per OSHA criteria

3. HAZARDS INFORMATION

EMERGENCY OVERVIEW: This material is used as a skeletal muscle relaxant. It is a potent drug, is highly toxic by ingestion and is highly toxic if it gets past the skin barrier. Target organs include skeletal muscle, the parasympathetic nervous system and the respiratory system.

ROUTE(S) OF ENTRY: Skin: Yes
Inhalation: Yes
Ingestion: Yes

MATERIAL SAFETY DATA SHEET

PAGE 2

Vecuronium Bromide for Injection

ISSUED 08/03/99

3. HAZARDS INFORMATION, continued

INGESTION RATING: Highly toxic *

SKIN ABSORPTION RATING: Highly toxic

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: N/D

TARGET ORGANS: Skeletal muscle, respiratory system, parasympathetic nervous system.

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L

ACGIH: N/L

None

SIGNS AND SYMPTOMS: N/D. In clinical use, adverse reactions include muscle weakness, paralysis, breathing difficulties, itching and redness and, rarely, bronchospasm, hypotension and/or increased heart rate, and rashes.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Hypersensitivity to skeletal muscle relaxants. Myasthenia gravis, Eaton-Lambert syndrome or neuromuscular disease. Respiratory ailments.

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Reversal of neuromuscular blockade can be achieved by administration of cholinesterase inhibitors such as neostigmine or edrophonium in conjunction with atropine or glycopyrrolate. Provide symptomatic/supportive care, monitoring respiratory function, as necessary.

MATERIAL SAFETY DATA SHEET

PAGE 3

Vecuronium Bromide for Injection

ISSUED 08/03/99

4. FIRST AID MEASURES, continued

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Reversal of neuromuscular blockade can be achieved by administration of cholinesterase inhibitors such as neostigmine, or edrophonium in conjunction with atropine or glycopyrrolate. Provide symptomatic/supportive care, monitoring respiratory function, as necessary.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Reversal of neuromuscular blockade can be achieved by administration of cholinesterase inhibitors such as neostigmine or edrophonium in conjunction with atropine or glycopyrrolate. Provide symptomatic/supportive care, monitoring respiratory function, as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Reversal of neuromuscular blockade can be achieved by administration of cholinesterase inhibitors such as neostigmine or edrophonium in conjunction with atropine or glycopyrrolate. Provide symptomatic/supportive care, monitoring respiratory function, as necessary.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: N/A

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/D

FIRE & EXPLOSION HAZARDS: N/D

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: Wear protective clothing and self contained breathing apparatus.

MATERIAL SAFETY DATA SHEET
Vecuronium Bromide for Injection

PAGE 4

ISSUED 08/03/99

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material and place into appropriate container for disposal according to Section 13.

7. HANDLING AND STORAGE

HANDLING: No special handling required.

STORAGE: Store dry powder at controlled room temperature of 15-30 degrees C (59-86 degrees F). Protect from light.

SPECIAL PRECAUTIONS: Protect from light.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required under normal use conditions.

RESPIRATORY PROTECTION: Respiratory protection is not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Eye protection is not required during typical product use conditions. Eye protection is recommended if contact is likely.

OTHER PROTECTION: N/D

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: White to off-white powder.

ODOR: N/D

BOILING POINT: N/A

MELTING/FREEZING POINT: 227-229 deg. C

VAPOR PRESSURE (mm Hg): N/A

VAPOR DENSITY (Air=1): N/A

MATERIAL SAFETY DATA SHEET

PAGE 5

Vecuronium Bromide for Injection

ISSUED 08/03/99

9. PHYSICAL AND CHEMICAL PROPERTIES, continued

EVAPORATION RATE: N/A

BULK DENSITY: N/D

SPECIFIC GRAVITY: N/A

SOLUBILITY: Water

pH: 3.3-4.5 for reconstituted solutions.

VISCOSITY: N/D

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: Powder is stable.

INCOMPATIBILITIES: N/D

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits toxic fumes of NOx and Br-.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION

ORAL TOXICITY: LD50 = 41-455 mg/kg in rats and mice.

DERMAL TOXICITY: N/D. LD50(SC) = 0.15-0.17 mg/kg in mice and rats.

INHALATION TOXICITY: N/D

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D

OCULAR IRRITATION: N/D

DERMAL SENSITIZATION: N/D

SPECIAL TARGET ORGAN EFFECTS: N/D. Vecuronium bromide is a nondepolarizing neuromuscular blocking agent used as a muscle relaxant during surgical procedures.

CARCINOGENICITY INFORMATION: N/D

MATERIAL SAFETY DATA SHEET

PAGE 6

Vecuronium Bromide for Injection

ISSUED 08/03/99

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS: Not Regulated

PROPER SHIPPING NAME: N/A

HAZARD CLASS: N/A

UN NUMBER: N/A

PACKING GROUP: N/A

REPORTABLE QUANTITY: N/A

IATA/ICAO STATUS: Not Regulated

PROPER SHIPPING NAME: N/A

HAZARD CLASS: N/A

UN NUMBER: N/A

PACKING GROUP: N/A

REPORTABLE QUANTITY: N/A

IMO STATUS: Not Regulated

PROPER SHIPPING NAME: N/A

HAZARD CLASS: N/A

UN NUMBER: N/A

PACKING GROUP: N/A

REPORTABLE QUANTITY: N/A

FLASH POINT: N/A

15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/L